1-50 of 87 technologies within Therapeutic RSS ATOM

Methods of Treating Cancer with PK1 or Aurora Kinase Inhibitors by Using Parkin as a Biomarker

2015-312 – Mayo Clinic has discovered that the Parkin protein is a mitotic regulator. Cancer cells with deficiency or mutations in Parkin have an increase in mitotic regulator expression leading to tumorigenesis and an increase in sensitivity of Pk1 and Aurora kinase inhibitors. This newly identified mechanism has revealed that Parkin mutations may be used as a biomarker for measuring the sensitivity of... Read More

Discovery of PD-L1 (a.k.a. B7-H1) Gene, Protein and Antibodies

1999-098 – Mayo Clinic has patent rights broadly claiming PD-L1 antibodies along with other PD-L1 related fundamental patent claims.

USP7 Inhibitors to Treat Breast Cancer

2016-117 – Mayo Clinic has discovered that the use of USP7 inhibitors sensitize HER2+breast cancer cells to existing HER2+ therapies.

CDK4/6 Inhibitors Prevent Cancer Metastasis

2016-055 – Mayo Clinic has discovered the functional roles for DUB3, an ubiquitin specific protease, and CDK4/6 inhibitors, in their ability to regulate cancer metastasis. CDK4/6 inhibitors blocked triple-negative breast cancer metastasis.

BET Inhibitors Sensitize Cancer Cells to PARP Inhibitors

2015-196 – Mayo Clinic has discovered that BET inhibitors hinder the homologous recombination process in DNA repair and that BET inhibitors sensitize tumors to PARP inhibitor treatment.

A Role of USP10 in AMPK Activation and mTOR Inhibition

2015-066 – Mayo Clinic has discovered that USP10, an ubiquitin protease, deubinquinates AMPK and inhibits mTOR activity. Activating USP10 could have therapeutic effects in treating diabetes and cancer.

Therapeutic Modulation of the MoCo Biosynthesis Pathway to Protect Neurons and Axons from Inflammation-Induced Injury

2014-299 – Mayo Clinic has developed an innovative therapeutic strategy to use molybdenum cofactor (MoCo) to treat neurological inflammatory disease.

Targeting Therapy for B7-H1 Tumors

2014-207 – Mayo Clinic has discovered a therapeutic pathway to target PD-L1 (a.k.a. B7-H1) positive tumors. Inhibition of DNA-PKcs function restores the sensitivity of PD-L1 positive tumors to chemotherapy by two fold.

Meningioma Treatment

2010-312 – The invention relates to the treatment of meningiomas using a composition including a cytotoxic agent and a compound selected from phenylbenzothiazole derivatives, stilbene derivatives, and biphenylalkyne derivatives.

Development and Use of Naturally Mutated Proteins as Vaccines for the Treatment of Cancers

2012-209 – Mayo Clinic researchers have developed methods and materials for treating cancer through the use of antigen combinations. For example, Vesicular Stomatitis Virus (VSV) vectors designed to express a GNAQ antigen, a TYRP1 anti-gen, and an N-RAS antigen can be used to reduce the number of cancer cells (e.g., uveal melanoma cells) within a mammal. In some cases, VSV vectors designed to express... Read More

Avian Influenza A/H5N1 Vaccine

2015-151 – Several novel naturally processed and HLA presented influenza A/H5N1-derived peptides from a class I HLA-A0201 molecules have been identified. A mass spectrometry approach was used to identify five influenza peptides from a B-cell line (homozygous for HLA-A0201) after infection with influenza A/H5N1 virus. The immunologic relevance and specificity of these identified influenza-derived... Read More

TGR5-Targeted Therapies for Cholangiopathies

2014-321 – TGR5 antagonist for the treatment of cholangiopathies including polycystic liver disease.

Novel Stearoyl CoA Desaturase 1 (SCD1) Inhibitors

2014-229 – Computer modeling followed by synthesis of novel compounds and testing for stearoyl CoA desaturase 1 (SCD1) specific growth inhibition of cancer cells has led to the identification of four novel lead SCD1 inhibitors.

Stearoyl-CoA Desaturase 1-Targeted Therapy

2012-062 – Broad patent claims have issued claiming methods for treating renal cell carcinoma by using SCD1 inhibitors and are available for licensing.

Novel Prodrugs of KATP Channel Openers to Treat Glaucoma

2013-312 – A series of novel prodrugs of K channel openers demonstrated significant intraocular pressure (IOP) lowering in normal mice and in a mouse model of glaucoma. The IOP lowering response obtained from using a K channel openers prodrug combined with other glaucoma drugs on the market seems to be somewhat synergistic

Triple Reuptake Inhibitors for the Treatment of Depression

2011-044 – Technology Description Triple reuptake inhibitors (TRIs) are a relatively new class of antidepressants that impact dopamine, serotonin and norepinephrine neurotransmission. Mayo Clinic researchers, in collaboration with researchers from Virginia Tech, developed a novel TRI (PRC200-SS) with potent transporter binding and efficacy in mouse behavioral models. A large pharmaceutical company... Read More

Potent Blocker of the Norepinephrine Transporter

2000-090 – Novel small molecule compounds that selectively inhibit norepinephrine, serotonin and dopamine reuptake have been developed. Specifically, the invention provides amine compounds, methods for synthesizing amine compounds, and methods for inhibiting neurotransmitter reuptake. The amine compounds provided herein can be used as potent, wide-spectrum antidepressant medications for inhibiting... Read More

Regulation of Fracture Repair and Bone Formation by Prostacyclin

2013-288 – The balance between bone loss and deposition is important for normal bone growth and remodeling, and depends on a complex interplay between the resident bone cells: osteoclasts, osteoblasts, and osteocytes. Here we show enhanced cellular production of prostacyclin and increased intra-cellular concentrations of prostacyclin synthase in osteocytes derived from sclerostin knockout mice.... Read More

Mouse Model

Novel Mouse Model Allowing for Inducible and Cell-type Specific Expression of Human apoE3 or apoE4

2013-105 – The ε4 allele of the apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset Alzheimer’s disease (AD) compared to the more common ε3 allele. Studies in animal models and humans suggest that apoE4 exhibits both loss-of-function and gain-of-toxic-function compared to apoE3. In regulating amyloid pathology, apoE4 is less efficient than apoE3 in mediating the clearance of... Read More

30 Day Readmission Risk Stratification Tool

2013-015 – This is an automated tool that assigns a risk score to patients as they are admitted and move through their hospital course. It makes the patient risk factors as well as potential interventions to reduce the risk of readmission transparent to the patient’s care team, closing the loop on the process. We are utilizing AMALGA from Microsoft but the value is in the scoring methodology as a... Read More

Mechanical, Time-based, Probiotic Delivery Device

2013-005 – Mechanical, Time-based, Probiotic Delivery Device.

Brachytherapy Co-delivery Improvements

2012-182 – Lung cancer is the leading couse of cancer deaths in the United States. Lobectomy is the gold standard extent of resection for most lung cancers, but some patients are poor candidates for lobectomy due to poor pulmonary health/function and/or other comorbities. Sublobar resection, the removal of less than a lobe of the lung, is a compromise procedure for these patients in that it allows for... Read More

Cutting Device For Stricturoplasty or Pyloroplasty

2012-150 – Patients who develop obstruction in the gastrointestinal track due to inflammatory strictures, or failure of sphincter muscles to relax, are benefitted by relief of that obstruction. Mayo has developed a device to stabilize the position and control length and depth. The device can be used in an lumen (gastrointestinal, vascular, urologic, gynecologic, pulmonary etc).

B Cells in the Diagnosis and Treatment of Amyotrophic Lateral Sclerosis (ALS)

2012-112 – We have identified abnormalities in the B cell compartment in the circulation of patients with ALS. This abnormality could be used to develop a test to measure the prognosis of patients with ALS or to diagnose patients with different forms of the disease. Additionally, the involvement of B cells in the pathology of ALS will lead treatments that may ameliorate the disease or its symptoms.

Agelastatin A as a Treatment for CNS Lymphoma, Tumors

2012-098 – Agelastatin A (AA) is an anti-neoplastic agent with anti-osteopontin (OPN) activity. Brain tumors often express OPN significantly. A comprehensive chemoinformatic analysis followed by in vivo pharmacokinetic evaluations in mice is performed. CNS penetration of AA is about 10%. AA should be further tested for activity against brain tumors.

Apoptotic Response to DNA Damage in Pluripotent Stem Cells Facilitates Pharmacologic Purging of Teratoma Forming Progenitor Cells

2012-090 – Pluripotent stem cells have been the focus of bioengineering efforts designed to generate regenerative products, yet harnessing therapeutic capacity while minimizing the risk of dysregulated growth remains a formidable challenge. The risk of residual undifferentiated stem cells within differentiated progenitors requires a targeted approach to eliminate contaminating cells prior to in vivo... Read More

Corporal Body Evaluation, Endoscopy, and Associated Instrumentation

2012-073 – Erectile dysfunction (ED) is estimated to affect 20-30% of men between the ages of 40-80 years. In cases of medication-resistant ED, surgical treatment, and especially penile prosthesis implantation is the standard of care. Complications of surgery can include neurovascular and urethral injury, and other tissue damage that can contribute to sub-optimal outcomes. A Mayo Clinic investigator... Read More

Inhibitors of the Signal Transducer and Activator of Transcription 3 (STAT3) Pathway and Their Uses

2012-055 – Background Transcription factor STAT3 plays an active role in the initiation and proliferation of malignant brain tumors. Thus, small molecule STAT3 inhibitors have potential as therapeutic agents for malignant gliomas as well as other STAT3-dependent tumors. Technology Description Mayo Clinic Researchers have synthesized a series of novel compounds to block the STAT3 pathway. These... Read More

VSV-N-RAS, VSV-TYRP1 or VSV-CYT-C Viruses for the Treatment of Melanoma

2012-050 – We have shown that a combination of these vesicular stomatis viruses (VSV) that encode N-Ras, cytochrome c (ctyc), or Tyrosinase-related protein 1(TYRP1), can be used to treat melanoma. Previously, we had shown that the use of a cDNA library in packaged in VSV can treat cancer. Here we show that a combination of three particular VSVs with the cDNA of N-Ras, cyt-c and Tryp 1 given... Read More

Nuclear Reprogramming Through Oxygen-Independent Metabotype Purges Dysfunctional Mitochondrial Heteroplasmy

2012-007 – Mitochondrial disease is inherited through maternal transmission of mutated mitochondrial DNA (mtDNA) with disease phenotypes determined by the unpredictable mixture of mutant and wild-type mtDNA. Mitochondrial heteroplasmy is dependent upon stochastic segregation of mtDNA into discrete units during early embryogenesis as mtDNA replication is shut off during blastomere expansion. Since... Read More

Information Bypass for Limb Reanimation

2012-004 – What is envisioned is a system of electrochemical and electrical monitoring coupled with directed stimulation to bypass damaged nerve tissue. The combination of information detection, conversion algorithm and programmed stimulation will provide regeneration of the neural commands. Further it is envisioned that a pump can be added to provide neural modular/growth factors to maintain the nerve... Read More

A Novel Translocation Involving TP63 and TBL1XR1 Resulting in a Dominant Negative TP63 Isoform

2011-271 – We identified a novel translocation of TP63 gene which encodes p63 protein. The translocation leads to overexpression of a dominant negative TP63 isoform. Dominant negative TP63 isoforms lead to inactivation of p53, the most important tumor suppressor known. The translocation can be useful for diagnosis and subclassification of certain peripheral T cell lymphomas, B-cell lymphomas... Read More

Processed Acellular Nerve Allograft

2011-226 – The segmental loss of peripheral nerve may result from open or closed extremity trauma, resection of benign or malignant primary nerve tumors, or limb-sparing tumor surgery. Currently available reconstructive options include vascularized and conventional (nonvascularised) nerve autografts, nerve conduits from a variety of materials, nerve allografts and nerve transfer. Of these, autografting... Read More

Continent Stomal Occlusion Device

2011-188 – Ileostomy or colostomy are common permanent bowel procedures performed for inflammatory disease, trauma, or cancer. The development of an internal reservoir, obviating the need for an external appliance, has been hampered by the need for an interface between living tissue and the device. The invention disclosed herein is an adaptation of a floating ball valve. Within the bowel lumen lies a... Read More

Methods and Materials for Assessing Responsiveness PARP Inhibitors and Platinating Agents

2011-184 – Methods and Materials for Assessing Responsiveness PARP Inhibitors and Platinating Agents Methods and materials have been developed for assessing responsiveness to PARP inhibitors and platinating agents by using levels of non-homogous end-joining (NHEI) pathway members to determine if cancer cells that are homologous recombination (hr) - deficient are likely to be susceptible or resistant... Read More

Mutations in the KCND3-Encoded Kv4.3 Potassium Ion Channel and Use in Diagnostic Methodologies for the Detection of Sudden Death-Predisposing Cardiac Channelopathies

2011-122 – The present invention details mutations in the KCND3-encoded Kv4.3 potassium ion channel that are associated with sudden death predisposing genetic conditions such as Brugada syndrome (BrS) and long QT syndrome (LQTS) and the mechanism by which at risk individuals can be screend for potentially life threatening mutation isn this gene. This invention is based on the that mutations within the... Read More

Targeting CD3ye to Induce Therapeutic T Cell Death

2011-092 – T cells drive adaptive immune responses that can turn out pathogenic when directed against your own body tissues and organs causing autoimmune diseases. On the other hand, T cells are the main cellular component driving acute organ rejection after transplantation. Therefore different strategies to deplete/inactivate T cells have been pursued to treat patients either suffering from autoimmime... Read More

Vaccine Virus Membrane Protein HLA Class II-Restricted T Cell Epitopes

2011-065 – Three decades after the eradication of smallpox, the threat of bioterrorism and outbreaks of emerging diseases such as monkeypox have renewed interest in the development of safe and effective next-generation poxvirus vaccines and biodefense research. Current smallpox vaccines contain live virus and are contraindicated for a large percentage of the population. Safer, yet still effective... Read More

DNA Aptamers Promoting Remyelination in Neurodegenerative Disease

2011-042 – DNA Aptamers Promoting Remyelination in Neurodegenerative Disease Single-stranded DNA aptamers 40 nucleotides in length were selected for binding to mouse myelin and were evaluated for their ability to promote remyelination. This approach was based upon previous reports indicating that IgM antibodies are capable of promoting remyelination in animal models of multiple sclerosis. After... Read More

RU486 for Decreasing Suppressive Monocytes in Cancer and Sepsis

2011-027 – RU486 for Decreasing Suppressive Monocytes in Cancer and Sepsis Suppressive monocytes have been found in a number of different conditions including sepsis, cancer, and trauma victims. Presence of large numbers of these cells (typically CD14+/DR-) is predictive of poor prognosis. Suppressive monocytes contribute to systemic immune suppression, prevent the differentiation of monocytes into... Read More

Treating Obesity by Modulating the Microbiome in the Human Gut

2011-018 – Technology Description Several recent studies suggest that the microbiome bacterial community of an individual’s gut may play a role in obesity by increasing or decreasing that individual’s energy harvesting efficiency of its caloric intake. Obese individuals contain bacterial species that are known to ferment carbohydrates to acetate and other short-chain fatty acids. These fatty acids are... Read More

Transpulmonary Induction of Therapeutic Hypothermia (In Collaboration with Minnesota High-Tech Resources LLC)

2010-284 – Therapeutic hypothermia is a widely accepted methodology for mitigating injury to vital organs following ischemic insults. Cellular metabolism decreases with lower temperatures and this reduction in metabolism protects metabolically active organs including the heart and brain during episodes of ischemia and hypoxia. Therapeutic hypothermia is currently practiced in association with a number... Read More

Enhancing T Cell Activation Using Altered MHC-Peptide Ligands

2010-271 – The normal immune system contains T cells bearing antigen receptors which are not readily reactive to self. This invention describes a new method for activating self-reactive T cells in a peptide specific manner, a strategy designed to focus autoimmune cellular responses against cancers and persisting virus infections.

Mouse Model

Humanized Mouse Models to Examine Therapeutic Response

2010-206 – Patient derived tumor tissue samples that have been demonstrated to grow in mice.

Esophageal Endoscopic Mucosectomy

2010-177 – Background: The incidence of Barrett’s esophagus and esophageal adenocarcinoma (EAC) is rising in Western nations, and, according to the National Cancer Institute, EAC is the fastest growing form of cancer in the United States. Esophagectomy is standard treatment for Barrett’s esophagus with high grade dysplasia and malignancy. However, due to high morbidity rates associated with... Read More

Anxiety App

Anxiety Treatment App

2010-162 – The application works on the iPod Touch and iPhone platform and will improve access to exposure-based therapy for individuals with anxiety disorders. The application can be used independently as a self-help program or in conjunction with a health professional. To Access the App through the iTunes Store, click on the link below. AnxietyCoach App

Cancer Vaccines Utilizing Vesicular Stomatitis Virus Delivery of Antigens

2009-374 – Technology Description An immunotherapy approach that delivers multiple antigens within a vesicular stomatitis virus (VSV) vector. The delivery of multiple antigens allows for a multipronged immune response against a tumor while the VSV vector serves as an activator of the innate and adaptive immune response. A three antigen combination delivered via a VSV vector has been demonstrated to be... Read More

Insulin-Stimulating Peptides for Diabetes and Metabolic Disorders

2009-173 – Insulin-Stimulating Peptides for Diabetes and Metabolic Disorders Mayo Clinic Researchers have developed a series of peptides that have been shown to modulate glucose levels and reduce fibrotic damage to the heart and kidneys in diabetic animal models. These peptides are structural analogs of glucagon-like peptide (GLP) and natriuretic peptides. Application Control of glucose levels in... Read More

Creation of a Peptide with Glucagon-like Peptide-1 (GLP-1) Properties

2009-172 – Glucagon-like peptide-1 (GLP-1) is derived from the transcription product of the proglucagon gene and is currently used for the management of DM. We have created a peptide with GLP-1 Properties.

Peptides for Delivering Agents Across the Blood-Brain Barrier

2009-139 – Technology Description Mayo Clinic researchers have exploited normal blood-brain barrier (BBB) transport mechanisms utilized by apolipoproteins to deliver agents across the BBB and have designed peptides incorporating apolipoprotein LDL receptor binding sequences. These peptides contain additional amino acid sequences to facilitate the binding and delivery of various biological and chemical... Read More

Page 1 of 2 12